Home › Research › Brain scans and imaging
Disease stage–specific atrophy markers in Alzheimer's disease
Hannah Baumeister, Helena Marie Gellersen, Sarah E. Polk, René Lattmann, Anika Wuestefeld, Laura E.M. Wisse, Trevor W. Glenn, Renat Yakupov et al.. Alzheimer s & Dementia, 2025-07-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Accelerated atrophy of medial temporal lobe subregions was evident already during preclinical AD. Symptomatic disease stages most notably differed in their hippocampal and parietal atrophy signatures. Atrophy-cognition relationships varied by intended use and disease stage. With the appropriate marker, MRI can detect abnormal atrophy already during preclinical AD. To optimize performance, atrophy markers should be tailored to the targeted disease stage and intended use. HIGHLIGHTS: Subregional atrophy markers detect ongoing atrophy in preclinical Alzheimer's disease (AD). Subjective cognitive decline in preclinical AD links to manifest atrophy. Optimal atrophy markers differ by the disease stage and intended use.
What this study adds
Evidence grade: Low
The record lists 363 participants. MRI atrophy markers detected abnormal shrinkage in medial temporal lobe subregions already during preclinical Alzheimer's disease, and the best marker differed by disease stage and intended use. This is about improving detection and staging, not about treating, curing, or preventing the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Baumeister, H., Gellersen, H. M., Polk, S. E., Lattmann, R., Wuestefeld, A., Wisse, L. E., et al. (2025). Disease stage–specific atrophy markers in Alzheimer's disease. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70482
Vancouver
Baumeister H, Gellersen HM, Polk SE, Lattmann R, Wuestefeld A, Wisse LE, et al. Disease stage–specific atrophy markers in Alzheimer's disease. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70482. PMID: 40691867.
BibTeX
@article{baumeister2025-40691867,
author = {Baumeister, Hannah and Gellersen, Helena Marie and Polk, Sarah E. and Lattmann, René and Wuestefeld, Anika and Wisse, Laura E.M. and Glenn, Trevor W. and Yakupov, Renat and others},
title = {{Disease stage–specific atrophy markers in Alzheimer's disease}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.70482},
pmid = {40691867},
url = {https://doi.org/10.1002/alz.70482}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Accelerated atrophy of medial temporal lobe subregions was evident already during preclinical AD.
- Symptomatic disease stages most notably differed in their hippocampal and parietal atrophy signatures.
- Atrophy-cognition relationships varied by intended use and disease stage.
- With the appropriate marker, MRI can detect abnormal atrophy already during preclinical AD.
- To optimize performance, atrophy markers should be tailored to the targeted disease stage and intended use.
Why it matters
MRI atrophy markers detected abnormal shrinkage in medial temporal lobe subregions already during preclinical Alzheimer's disease, and the best marker differed by disease stage and intended use. This is about improving detection and staging, not about treating, curing, or preventing the disease.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Participants363
- Evidence strengthLow
How this study scored 52/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 50 of the 96 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 363 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 16 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 10.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | University of Cambridge: institution h-index 1,973 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 28 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40691867) |
| Free to read | 2 / 2 | Free to read |
| Points | 50 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 50 of the 96 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Brain scans and imaging from nearby years
Also in Brain scans and imaging
137 studies in the library are filed under Brain scans and imaging with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Brain scans and imaging hub.